Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Overview

This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.

Full Title of Study: “A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 1, 2025

Interventions

  • Drug: CC-96191
    • CC-96191

Arms, Groups and Cohorts

  • Experimental: CC-96191
    • CC-96191 will be administered intravenously on a 28-day Cycle

Clinical Trial Outcome Measures

Primary Measures

  • Dose limiting toxicities (DLTs)
    • Time Frame: Up to 42 days after the first dose
    • Are defined as toxicities that meet the protocol-specified criteria occurring within the DLT assessment window (Cycle 1, Days 1 to at least 28 and up to 42 days) that cannot be attributed to a clearly identifiable cause such as underlying illness, disease progression, other concurrent illness, or concomitant medication.
  • Maximum tolerated dose (MTD)
    • Time Frame: Up to 35 days after the last dose
    • Is defined as the highest dose at which less than 33% of the population treated with CC-96191 experience a dose limiting toxicity (DLT) in the first cycle.
  • Adverse Events (AEs)
    • Time Frame: Up to 35 days after the last dose
    • Type, frequency, seriousness, severity and relationship of AEs to CC-96191

Secondary Measures

  • Complete remission rate (CRR)
    • Time Frame: Up to approximately 2 years
    • As defined by the European Leukemia Net (ELN) AML response criteria.
  • Objective response rate (ORR)
    • Time Frame: Up to approximately 2 years
    • As defined by the European Leukemia Net (ELN) AML response criteria.
  • Progression-free survival (PFS)
    • Time Frame: Up to approximately 2 years
    • Is defined as the time from the first dose of CC-96191 to the first occurrence of disease progression or death from any cause.
  • Overall survival (OS)
    • Time Frame: Up to approximately 2 years
    • Is measured as the time from the first dose of CC-96191 to death due to any cause.
  • Duration of remission
    • Time Frame: Up to approximately 2 years
    • For subjects with best response of complete remission (CR) of any type, morphologic leukemia free state (MLFS) or partial remission (PR), duration of response (DOR) is measured from the time when criteria for CR/MLFS/PR are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented
  • Time to remission
    • Time Frame: Up to approximately 2 years
    • Time from the date of first dose to the earliest date of any response (CR of any type, MLFS or PR)
  • Pharmacokinetics – Cmax
    • Time Frame: Up to 35 days after last dose
    • Maximum serum concentration of drug
  • Pharmacokinetics – AUC
    • Time Frame: Up to 35 days after last dose
    • Area under the serum concentration time-curve
  • Pharmacokinetics – tmax
    • Time Frame: Up to 35 days after last dose
    • Time to peak (maximum) serum concentration
  • Pharmacokinetics – t1/2
    • Time Frame: Up to 35 days after last dose
    • Terminal half-life
  • Pharmacokinetics – CL
    • Time Frame: Up to 35 days after last dose
    • Total body clearance of the drug from the serum
  • Pharmacokinetics – Vss
    • Time Frame: Up to 35 days after last dose
    • Volume of distribution at steady-state
  • Presence of anti-drug antibodies (ADA)
    • Time Frame: Up to 35 days after last dose
    • Detection of anti-drug antibodies in participants
  • Frequency of anti-drug antibodies (ADA)
    • Time Frame: Up to 35 days after last dose
    • Frequency of anti-drug antibodies in participants

Participating in This Clinical Trial

Inclusion Criteria

Participants must satisfy the following criteria to be enrolled in the study: 1. Participant must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted. 3. Participant is ≥ 18 years of age at the time of signing the ICF. 4. Relapsed or refractory CD33 positive AML at last visit as defined by the World Health Organization (WHO) Classification who have failed or who are ineligible for or have refused all available therapies for AML which may provide clinical benefit. 6. Participant has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. 7. At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion without conditioning. 8. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and during the safety follow-up period. Exclusion Criteria:

The presence of any of the following will exclude a Participant from enrollment: 1. Participant is suspected or proven to have acute promyelocytic leukemia (FAB M3) based on morphology, immunophenotype, molecular assay, or karyotype. 2. Participant has received systemic anticancer therapy (including investigational therapy) or radiotherapy < 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment. Hydroxyurea is allowed to control peripheral leukemia blasts. 3. Participants with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant-related side effects). 4. Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing. 5. Participants on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted. 6. Participant has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2. 7. Participant has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening. 8. History of concurrent second cancers requiring active, ongoing systemic treatment. 9. Participant is known seropositive or active infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus or hepatitis C virus. 10. Impaired cardiac function or clinically significant cardiac diseases, as defined in the protocol . 11. Participant is a pregnant or lactating female.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Celgene
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bristol-Myers Squibb, Study Director, Bristol-Myers Squibb
  • Overall Contact(s)
    • BMS Study Connect Contact Center http://www.bmsstudyconnect.com, 855-907-3286, Clinical.Trials@bms.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.